EGFR and lung adenocarcinoma: For example, MET amplification can be detected after the treatment of the first generation of EGFR-tyrosine kinase inhibitor (EGFR-TKI), gefitinib or erlotinib, in EGFR-mutant lung adenocarcinomas, and the combination of EGFR-TKI and MET inhibitor is demonstrated to be an effective treatment [36].